1 / 19

Modeling of Acute R esistance to the HER2 Inhibitor , L apatinib , in Breast C ancer C ells

Modeling of Acute R esistance to the HER2 Inhibitor , L apatinib , in Breast C ancer C ells. Marc Fink & Yan Liu & Shangying Wang Student Project Proposal Computational Cell Biology 2012. Outline. Brief review of the project goal Boolean network model and results

reilly
Download Presentation

Modeling of Acute R esistance to the HER2 Inhibitor , L apatinib , in Breast C ancer C ells

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Modeling of Acute Resistance to the HER2 Inhibitor, Lapatinib, in Breast Cancer Cells Marc Fink & Yan Liu & Shangying Wang Student Project Proposal Computational Cell Biology 2012

  2. Outline • Brief review of the project goal • Boolean network model and results • Modeling with ODEs in VCell and COPASI • Analysis of cell survival rate • Summary and outlook

  3. Goals • Modeling the signaling pathway of HER2 inhibitor, Lapatinib, in Breast Cancer Cells • Analyze the influence factors of cell apoptosis • Explanation of cell survival rate after treatment 01/13

  4. Mechanistic (process) diagrams Death Lapatinib ?????? HER2 Survival PI3K PDK1 p AKT (PKB) Protein Translation p ER FoxO p FoxO p 14-3-3 Translocation Translocation Transcription FoxO FoxO Apoptotic genes Apoptosis FoxO FoxO Survival genes 02/13

  5. Flow chart and strategies IGF1R Lapatinib HER2 • Lack of experimental parameters => Boolean network • Better understanding of dynamics => ODEs • Analysis of survival rate => Stochastic simulation RAF AKT MEK FoxO ERK FASL RSK BIM BAD apoptosis 03/13

  6. Boolean network model IGF1R Lapatinib HER2 AKT FoxO Apoptosis Time steps => Average value of apoptosis is around 0.5 with simplification. BIM apoptosis 04/13

  7. Boolean network model IGF1R Lapatinib HER2 AKT FoxO Apoptosis FASL Time steps => Average apoptosis is around 0.6 with additional information. BIM apoptosis 04/13

  8. Boolean network model IGF1R Lapatinib HER2 RAF AKT MEK FoxO Apoptosis ERK FASL Time steps RSK => Results depend on the complexity, adding weights not possible. BIM BAD apoptosis 04/13

  9. Modeling with ODEs => 22 species and 32 reactions, reasonable rates???!!! 05/13

  10. Model reduction and modification Lapatinib HER2 Due to the importance of FOXO => Neglect the downstream and add the self regulation AKT FoxO Apoptosis

  11. Self regulation of FOXO Φ Φ FoxO* (z) FoxO_mRNA (x) FoxO_gene FoxO (y) => Bistability of the positive feedback loop 06/13

  12. Modified model => 14 species and 16 reactions 07/13

  13. Sensitivity analysis Binding of Laptinib to HER2 Dimerization of HER2 FOXO => Laptinib is important for cancer cell apoptosis 08/13

  14. Modeling with ODEs IV Deterministic simulations with parameter scan (Laptinib) => Laptinib is able to stimulate FOXO, crucial to apoptosis 09/13

  15. Analysis of cell survival rate • Random initial concentrations (with COPASI) => Laptinib is able to stimulate cancer cell apoptosis 10/13

  16. Analysis of cell survival rate • Stochastic simulation (with VCell and C) => Laptinib is able to stimulate cancer cell apoptosis 11/13

  17. Summary and outlook • Apoptosis pathway of breast cancer cell is modeled and analyzed with simplifications • Survival rate of cancer cell is analyzed • Laptinib induced cancer cell apoptosis is with certain probability Outlook • Improve the pathway model with more details by getting more rates from experiments • Validation of the model and survival rate 12/13

  18. Experience with the softwares COPASI vsVCell • Writing reactions + +++ • Checking parameters + +++ • Deterministic simulation +++ + • Stochastic simulation ++ + • Parameter scan +++ ++ • Sensitivity analysis +++ - • Visualization - +++ 13/13

  19. Thank you for your attention!

More Related